乌斯特基努马布在性结肠炎患者的安全性和有效性:来自大型现实研究的结果
Antonio Tursi1,2, Giammarco Mocci3, Franco Scaldaferri4,5
1Territorial Gastroenterology Service, ASL BAT, Andria, Italy.
Expert opinion on biological therapy
|January 22, 2024
概括
这项研究表明,乌斯特基努马布 (UST) 对性结肠炎 (UC) 患者在现实环境中有效且安全. 乌斯特基努马布 (UST) 在性结肠炎 (UC) 患者中实现了显著的临床缓解和响应率.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乌斯特基努马布 (UST) 是一种联素-12/联素-23受体对抗剂,已被批准用于性结肠炎 (UC).
- 有限的现实世界数据存在于UST在UC患者的有效性和安全性.
研究的目的:
- 评估乌斯特基努马布 (UST) 在性结肠炎 (UC) 患者的实际有效性和安全性.
主要方法:
- 一个多中心,回顾性,观察性队列研究.
- 主要终点包括临床缓解 (部分梅奥得分≤1) 和安全性.
- 二级终点包括24周无皮质固醇缓解,临床反应和便calprotectin的减少.
主要成果:
- 在256名UC患者中,临床缓解率在8周时为18.7%,在24周时为27.6%.
- 临床响应率在8周为53.2%,在24周为61.8%.
- 较少先前生物治疗的患者观察到有利的结局;不良事件和切除术是罕见的.
结论:
- 乌斯特基努马布 (UST) 在现实环境中证明了治疗性结肠炎 (UC) 的有效性和良好的安全性.
- 该研究支持基于观察到的疗效和安全性数据,用于UC管理的UST的使用.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease I: Ulcerative Colitis
187
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
187


